Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON

Executive Summary

AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON to take responsibility for J&J's core pharmaceutical business. As a J&J company group chairman, Bowman will oversee McNeil Pharmaceutical Ortho Pharmaceutical, and Cilag, J&J's European pharmaceutical group. Bowman's resignation from American Cyanamid was announced July 21. He will officially join J&J on Aug. 1. At American Cyanamid, Bowman was executive vice president heading the $1.4 bil. medical group, consisting of Lederle pharmaceuticals and the medical device operations, including Davis & Geck. Under Bowman, the Cyanamid medical businesses have been growing rapidly. Medical group earnings in 1986 were up 28% to $184 mil. ("The Pink Sheet" May 18, p. 5). In the July 21 press release, American Cyanamid CEO George Sella said "Bowman leaves a long legacy of strong research and development, marketing, manufacturing and organization."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel